Neumora Therapeutics, Inc.
NMRANasdaqCIK 1885522HealthcareFiscal year ends Dec 31
Reports and events: 56 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2023-11-0116:05 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-057424 |
| 2023-11-0116:01 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-23-268165 |
| 2023-10-0220:22 ET | SC 13D | Ownership report, active investor | 0001072613-23-000508 |
| 2023-09-1916:16 ET | 8-K | 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-237644 |
| 2023-09-1106:07 ET | S-1/A | Registration statement, amended | 0001193125-23-231902 |
| 2023-08-2517:03 ET | S-1 | Registration statement | 0001193125-23-221589 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 30, 2026, 16:11 ET. Listed shows no prices and gives no investment advice.